OBJECTIVES: To evaluate the consistency of T2DM management by French GPs in 2012 versus 2013 HAS guidelines that recommend modulating glycaemic objectives depending on patient’s profile. To assess current treatment need for T2DM patients. METHODS: A transversal study, based on the IMS LifeLinkTM prospective Diabetes Cohort linked to Electronic Medical Records database (Disease Analyzer) was used to investigate patients’ profiles (age, disease history and complications, renal impairment, cardiovascular events, co-morbidities), HbA1c, hypoglycaemic risk, self monitoring of blood glucose (SMBG), and BMI evolution, linked to the current treatment. RESULTS: 6,680 T2DM patients (56% men) were included in the 2012 study cohort. The mean age was 66.6 years (25% of patients above 75 years); 19% had moderate to severe renal impairment and 56% had cardiovascular history. The new HAS guidelines split patients into several categories with associated HbA1c objectives varying from 6.5% to 9% based on age, frailty, diabetes history, and co-morbidities. 4%, 35%, 43%, and 18% of diabetic patients were eligible for the 6.5%, 7%, 8%, and 9% HbA1c objectives respectively. It appears that 55% of the diabetic population were at risk of hypoglycaemia, age and long diabetes history being the major risk factors. Given the modulation of glycaemic objectives more patients reached the new HbA1c objectives (74% of patients) vs. previous guidelines (about 55%). In this representative cohort, SU were prescribed with no dosage adjustment to all patients and even more frequently to patients at risk of hypoglycaemia (60.6%) while DDP4i were prescribed to “healthy patients” mostly not at risk of hypoglycaemia (51.5%). CONCLUSIONS: A minority of T2DM patients (39%) are eligible for an HbA1c objective of 7% or below, highlighting their frailty. This survey also shows that more patients are reaching their HbA1c target. However many of them are receiving treatments they should not due to high risk of hypoglycaemia.